Therapy Detail

Therapy Name SKLB-23bb
Therapy Description

SKLB-23bb is a selective HDAC6 inhibitor, which may result in disruption of microtubule polymerization, inhibition of the cell-cycle, and induction of apoptosis (PMID: 29610282).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
SKLB-23bb HDAC Inhibitor 34 SKLB-23bb is a selective HDAC6 inhibitor, which may result in disruption of microtubule polymerization, inhibition of the cell-cycle, and induction of apoptosis (PMID: 29610282).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown breast cancer not applicable SKLB-23bb Preclinical - Cell line xenograft Actionable In a preclinical study, SKLB-23bb treatment inhibited tumor growth in breast cancer xenograft models (PMID: 29610282). 29610282
Unknown unknown colon cancer not applicable SKLB-23bb Preclinical - Cell line xenograft Actionable In a preclinical study, SKLB-23bb treatment resulted in antitumor efficacy in colon cancer cells, demonstrating decreased colony formation in vitro and inhibition of tumor growth in cell line xenograft models (PMID: 29610282). 29610282
Unknown unknown ovarian carcinoma not applicable SKLB-23bb Preclinical - Cell line xenograft Actionable In a preclinical study, SKLB-23bb treatment resulted in antitumor efficacy in ovarian carcinoma cells, demonstrating decreased colony formation in vitro and inhibition of tumor growth in cell line xenograft models (PMID: 29610282). 29610282
Unknown unknown B-cell lymphoma not applicable SKLB-23bb Preclinical - Cell line xenograft Actionable In a preclinical study, SKLB-23bb treatment inhibited tumor growth in B-cell lymphoma xenograft models (PMID: 29610282). 29610282
Clinical Trial Phase Therapies Title Recruitment Status